Restoring compromised blood-retina-barrier integrity with Netrin-1 overexpression
Cellular and Molecular Life Sciences · 2025
DOI: 10.1007/s00018-025-05903-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cellular and Molecular Life Sciences, 2025. Verfasst von Jessica Furtado und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, 06511, USA. Hauptthemen laut MEDLINE: Netrin-1, Blood-Retinal Barrier. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, American Heart Association, European Research Council.
Abstract (Originalsprache)
The blood-retina barrier (BRB) protects retinal neuronal function and enables vision. A compromised, leaky BRB is a hallmark of vision-threatening retinal diseases such as diabetic retinopathy (DR) and wet age-related macular degeneration (AMD) that affect millions of persons worldwide. Strategies to enhance BRB integrity hold promise as therapeutic interventions to prevent vision loss. Previous studies identified Netrin-1 ( NTN1 ) as a key regulator of BRB stability and revealed reduced Netrin-1 signaling in DR patients, suggesting that Netrin-1 supplementation could help preserve BRB function and prevent disease progression. Herein, we used inducible genetic NTN1 overexpression to investigate effects on BRB development and maintenance. We show that global NTN1 overexpression converted leaky vessels at the P5 angiogenic front into a non-leaky state. In pathological settings, NTN1 overexpression reinforced BRB integrity in oxygen-induced retinopathy (OIR), improving electroretinogram (ERG) amplitudes and rescued vascular leak in laser-induced choroidal neovascularization (CNV). NTN1 overexpression or Ntn1 knockout minimally and transiently affected retinal angiogenesis. Global Unc5b deletion phenocopied vascular leak observed in Ntn1 deficient retinas, while angiogenesis defects differed between Ntn1 and Unc5b knockouts. These findings establish Netrin-1 as a promising therapeutic target for preventing BRB breakdown in retinal vascular diseases and suggest that reinforcing the Netrin-1/Unc5b signaling pathway may provide a strategy to selectively stabilize the BRB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, 06511, USA.
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA.
- Department of Neuroscience, Yale University School of Medicine, New Haven, CT, 06511, USA.
- Paris Cardiovascular Research Center, Inserm U970, Université Paris, Paris, France.
- Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, CT, 06511, USA.
- Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, 06511, USA. anne.eichmann@yale.edu.
Förderung
- NEI NIH HHS
- American Heart Association
- European Research Council
- NHLBI Division of Intramural Research
- NHLBI NIH HHS
Zitieren
APA
Furtado, J., Zapadka, T. E., Park, H., Boyé, K., Demb, J. B., & Eichmann, A. (2025). Restoring compromised blood-retina-barrier integrity with Netrin-1 overexpression. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-025-05903-6
Vancouver
Furtado J, Zapadka TE, Park H, Boyé K, Demb JB, Eichmann A. Restoring compromised blood-retina-barrier integrity with Netrin-1 overexpression. Cellular and Molecular Life Sciences. 2025. doi:10.1007/s00018-025-05903-6
BibTeX
@article{Furtado2025,
author = {Furtado, Jessica and Zapadka, Thomas E and Park, Hyojin and Boyé, Kevin and Demb, Jonathan B and Eichmann, Anne},
title = {Restoring compromised blood-retina-barrier integrity with Netrin-1 overexpression},
journal = {Cellular and Molecular Life Sciences},
year = {2025},
doi = {10.1007/s00018-025-05903-6}
}
EUVIMED